BSX vs MDT
Boston Scientific and Medtronic, both Healthcare
Medtronic is the larger company at $102B against $67B. On trailing earnings BSX is the cheaper of the two at a P/E of 17.3 against 21.7, a gap that is only a bargain if the two are growing at similar rates. Over the past year MDT returned -5.3% against -56% for BSX. The RyuScore puts BSX ahead, 65 against 62 out of 100.
| Figure | BSX | MDT |
|---|---|---|
| Last close | $42.74 | $88.48 |
| Market cap | $67B | $102B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 17.3 | 21.7 |
| Dividend yield | n/a | 3.2% |
| 1-year return | -56% | -5.3% |
| 5-year return | -3.3% | -21% |
| RyuScoresector-relative, 1–10 | 65/100 | 62/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Boston Scientific
Revenue of $5.4B in Q2 2026, net income $905M. Its largest reported line is Electrophysiology EP, 18% of the disclosed total.
Medtronic
Revenue of $9.8B in Q1 2027, net income $1.5B. Its largest reported line is Total Other Countries Excluding Ireland, 100% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.